Hypertriglyceridemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hypertriglyceridemia – Drugs In Development, 2024 report and make more profitable business decisions.
Hypertriglyceridemia is a condition in which the blood contains high levels of triglycerides, a type of fat that provides energy to the body. Triglycerides are important for normal metabolism, but excess amounts can increase the risk of cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hypertriglyceridemia can also cause acute pancreatitis, a serious inflammation of the pancreas that requires medical attention. Hypertriglyceridemia can be caused by genetic factors, obesity, diabetes, sedentary lifestyle, alcohol consumption, and certain medications. The diagnosis is based on a blood test that measures the fasting triglyceride level. A normal level is below 150 mg/dL, while a very high level is above 500 mg/dL. The treatment of hypertriglyceridemia involves lifestyle modifications, such as weight loss, exercise, dietary changes, and alcohol reduction. In some cases, medication may be prescribed to lower the triglyceride level and prevent complications.
The Hypertriglyceridemia drugs in development market research report provide comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hypertriglyceridemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 42 molecules, with 39 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hypertriglyceridemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hypertriglyceridemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hypertriglyceridemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
89bio IncArrowhead Pharmaceuticals Inc
Beijing GeneCradle Technology Co Ltd
Bio-Thera Solutions Ltd
Cardax Inc
Centeer BioTherapeutics Ltd Co
Columbia University
Eddingpharm Inc
Eli Lilly and Co
HighTide Therapeutics Inc
Huons Co Ltd
Inversago Pharma Inc
Ionis Pharmaceuticals Inc
Korea United Pharm Inc
Kowa Co Ltd
Kyttaro Ltd
Liid Pharmaceuticals Inc
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Marea Therapeutics
MediciNova Inc
Mochida Pharmaceutical Co Ltd
NorthSea Therapeutics BV
Novo Nordisk AS
Nubiyota LLC
OrsoBio Inc
Peking University
Rivus Pharmaceuticals Inc
Saliogen Therapeutics Inc
Sirnaomics Ltd
University of Cincinnati
Viking Therapeutics Inc
Visirna Therapeutics HK Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hypertriglyceridemia reports